Long-Term Cardiac and Pulmonary Complications of Cancer Therapy

Hematology/Oncology Clinics of North America

Volumn 22, Issue 2, 2008, Pages 305-318

  Yahalom, Joachim ^a   Portlock, Carol S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IDARUBICIN; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PREDNISONE; RAZOXANE; RITUXIMAB; TAXANE DERIVATIVE; TRASTUZUMAB; VINBLASTINE; VINCRISTINE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVOR; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; HEART; HEART DISEASE; HODGKIN DISEASE; HUMAN; ISCHEMIC HEART DISEASE; LONG TERM CARE; LUNG TOXICITY; NONHUMAN; PERICARDITIS; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; VALVULAR HEART DISEASE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIOTOXINS; HEART; HEART DISEASES; HUMANS; LUNG; LUNG DISEASES; NEOPLASMS; RADIOTHERAPY; SURVIVORS;

EID: 41349109949     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2008.01.010     Document Type: Review

References (78)

1. Jones R.L., Swanton C., and Ewer M. Anthracycline cardiotoxicity. Expert Opin Drug Saf 5 6 (2006) 791-809
2. Jones R.L., and Ewer M.S. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. [review]. Expert Rev Anticancer Ther 6 9 (2006) 1249-1269
3. Keefe D.L. Anthracycline-induced cardiomyopathy. Semin Oncol 28 12 (2001) 2-7
4. Giantris A., Abdurrahman L., Hinkle A., et al. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 27 1 (1998) 53-68
5. Massin M.M., Dresse M.F., Schmitz V., et al. Acute arrhythmogenicity of first-dose chemotherapeutic agents in children. Med Pediatr Oncol 39 (2002) 93-98
6. Kremer L.C.M., van der Pal H.J.H., Offringa M., et al. Frequency and risks factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 13 (2002) 819-829
7. Lipshultz S.E., Lipsitz S.R., Sallan S.E., et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 23 12 (2005) 2629-2636
8. Nousiainen T., Jantunen E., Vanninen E., et al. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 86 (2002) 1697-1700
9. Mitani I., Jain D., Joska T.M., et al. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol 10 (2003) 132-139
10. Suter T.M., and Meier B. Detection of anthracycline-induced cardiotoxicity: is there light at the end of the tunnel?. Ann Oncol 13 5 (2002) 647-649
11. van Dalen E.C., Michiels E.M., Caron H.N., et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 4 (2006) CD005006
12. van Dalen C.D., van der Pal H.J.H., Caron H.N., et al. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. [review]. Cochrane Database Syst Rev 4 (2006) CD005008
13. Swain S.M., Whaley F.S., Gerber M.C., et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15 (1997) 1318-1332
14. Minotti G., Menna P., Salvatorelli E., et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. [review]. Pharmacol Rev 56 2 (2004) 185-229
15. Clark G.M., Tokaz L.K., Von Hoff D.D., et al. Cardiotoxicity in patients treated with mitoxantrone on Southwest Oncology Group phase II protocols. Cancer Treatment Symposia 3 (1984) 25-30
16. Arbuck S.G., Strauss H., Rowinsky E., et al. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr 15 (1993) 117-130
17. Giordano S.H., Booser D.J., Murray J.L., et al. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res 8 (2002) 3360-3368
18. Biganzoli L., Cufer T., Bruning P., et al. Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European organization for research and treatment of cancer multicenter trial. Cancer 97 (2003) 40-45
19. Gianni L., Dombernowsky P., Sledge G., et al. Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. Ann Oncol 12 (2001) 1067-1073
20. Tan-Chiu E., Yothers G., Romond E., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23 31 (2005) 7811-7819
21. Holmes F.A., Madden T., Newman R.A., et al. Sequence-dependent alteration of doxorubicin pharmacokinetic by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14 10 (1996) 2713-2721
22. Chan S., Friedrichs K., Noel D., et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17 8 (1999) 2341-2354
23. Crone S.A., Zhao Y.Y., Fan L., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8 5 (2002) 459-465
24. Ozcelik C., Erdmann B., Pilz B., et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 99 13 (2002) 8880-8885
25. Chien K.R. Herceptin and the heart-a molecular modifier of cardiac failure. N Engl J Med 354 8 (2006) 789-790
26. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 8 (2006) 809-820
27. Smith K., Dang C., and Seidman A.D. Cardiac dysfunction associated with trastuzumab. Expert Opin Drug Saf 5 5 (2006) 619-629
28. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20 5 (2002) 1215-1221
29. Carver J.R., Shapiro C.L., Ng A., et al. American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: cardiac and pulmonary late effects. J Clin Oncol 25 (2007) 3991-4008
30. Amronim G.D., and Solomon R.D. Production of arteriosclerosis in the rabbit: a quantitative assessment. Arch Pathol 75 (1965) 219
31. Gold H. Production of arteriosclerosis in the rat: effect of X-ray and high-fat diet. Arch Pathol 71 (1961) 268
32. Artom C., Lofton H.B., and Clarkson T.B. Ionizing radiation atherosclerosis and lipid metabolism in pigeons. Radiat Res 26 (1965) 165
33. McEniery P.T., Dorosti K., Schiavone W.A., et al. Clinical and angiographic features of coronary artery disease after chest irradiation. Am J Cardiol 60 (1987) 1020
34. Boivin J.F., Hutchison G.B., Lubin J.H., et al. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 69 (1992) 1241
35. Hancock S.L., Tucker M.A., and Hoppe R.T. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 270 (1993) 1949
36. Henry-Amar M., Hayat M., and Meerwaldt J.H. Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. Int J Radiat Oncol Biol Phys 19 (1990) 1155
37. Mauch P., Kalish L., Marcus K.C., et al. Long-term survival in Hodgkin's disease. Cancer J Sci Am 1 (1995) 33
38. Glanzmann C., Kaufmann P., Jenni R., et al. Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiother Oncol 46 (1998) 51
39. Reinders J.G., Heijmen B.J., Olofsen-van Acht M.J., et al. Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up. Radiother Oncol 51 (1999) 35
40. Swerdlow A.J., Higgins C.D., Smith P., et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 99 (2007) 206-214
41. Aleman B.M., van del Belt-Dusebout A.W., De Bruin M., et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109 (2007) 1878-1886
42. Handler C.E., Livesey S., and Lawton P.A. Coronary ostial stenosis after radiotherapy: angioplasty or coronary artery surgery?. Br Heart J 61 (1989) 208
43. Orzan F., Brusca A., Conte M.R., et al. Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br Heart J 69 (1993) 496
44. Lund M.B., Kongerud J., Boe J., et al. Cardiopulmonary sequelae after treatment for Hodgkin's disease: increased risk in females?. Ann Oncol 7 (1996) 257
45. Aviles A., Neri N., Nambo M.J., et al. Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma 46 (2005) 1023-1028
46. Host H., Brennhoud I.O., and Loeb M. Post-operative radiotherapy in breast cancer: long-term results from the Oslo study. Int J Radiat Oncol Biol Phys 12 (1986) 727
47. Jones J.M., and Ribeiro G.G. Mortality patterns over 34 years of breast cancer patients in a clinical trial of post-operative radiotherapy. Clin Radiol 40 (1989) 204
48. Haybittle J.L., Brinkley D., Houghton J., et al. Postoperative radiotherapy and late mortality: evidence from the Cancer Research Campaign trial for early breast cancer. BMJ 298 (1989) 1611
49. Hooning M.J., Berthe A., Aleman M.P., et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 99 (2007) 365-375
50. Giordano S.H., and Hortobagyi G.N. Local recurrence of cardiovascular disease: pay now or later. J Natl Cancer Inst 99 (2007) 340-341
51. Darby S.C., McGale P., Taylor C.W., et al. Long-term mortality from heart disease and lung cancer after radiotherapy breast cancer: prospective cohort study of about 300,000 women in US SEE registries. Lancet Oncol 6 (2005) 539-540
52. Giordano S.H., Juo Y.F., Freeman J.L., et al. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 97 (2005) 406-407
53. Stegman L.D., Beal K.P., Hunt M.A., et al. Long-term clinical outcomes of whole-breast irradiation delivered in the prone position. Int J Radiat Oncol Biol Phys 68 (2007) 73-81
54. Landau D., Adams E.J., Webb S., et al. Cardiac avoidance in breast radiotherapy: a comparison of simple shielding techniques with intensity-modulated radiotherapy. Radiother Oncol 60 (2001) 247
55. Shapiro C.L., Hardenbergh P.H., Gelman R., et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 16 (1998) 3493
56. Savage D.E., Constine L.S., Schwartz R.G., et al. Radiation effects on left ventricular function and myocardial perfusion in long-term survivors of Hodgkin's disease. Int J Radiat Oncol Biol Phys 19 (1990) 721
57. Pierga J.Y., Maunoury C., Valette H., et al. Follow-up thallium-201 scintigraphy after mantle field radiotherapy for Hodgkin's disease. Int J Radiat Oncol Biol Phys 25 (1993) 871
58. Pihkala J., Happonen J.M., Virtanen K., et al. Cardiopulmonary evaluation of exercise tolerance after chest irradiation and anticancer chemotherapy in children and adolescents. Pediatrics 95 (1995) 755
59. Piovaccari G., Ferretti R.M., Prati F., et al. Cardiac disease after chest irradiation for Hodgkin's disease: incidence in 108 patients with long follow-up. Int J Cardiol 49 (1995) 39
60. Reber D., Birnbaum D.E., and Tollenaere P. Heart disease following mediastinal irradiation: surgical management. Eur J Cardiothorac Surg 9 (1995) 202-205
61. Van Son J.A., Noyez L., and van Asten W.N. Use of internal mammary artery in myocardial revascularization after mediastinal irradiation. J Thorac Cardiovasc Surg 104 (1992) 1539
62. Adams M.J., Lipshutz S.E., Schwartz C., et al. Radiation-associated cardiovascular disease: manifestations and management. Semin Radiat Oncol 13 (2003) 346
63. Ruckdeschel J.C., Chang P., Martin R.G., et al. Radiation-related pericardial effusions in patients with Hodgkin's disease. Medicine 54 (1975) 245
64. Arsenian M.A. Cardiovascular sequelae of therapeutic thoracic radiation. Prog Cardiovasc Dis 33 (1991) 299
65. Lagrange J.L., Darcourt J., Benoliel J., et al. Acute cardiac effects of mediastinal irradiation: assessment by radionuclide angiography. Int J Radiat Oncol Biol Phys 22 (1992) 897
66. Adams M.J., Lipsitz S.R., Colan S.D., et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 22 (2004) 3139-3148
67. Clements I.P., Davis B.J., and Wiseman G.A. Systolic and diastolic cardiac dysfunction early after the initiation of doxorubicin therapy: significance of gender and concurrent mediastinal radiation. Nucl Med Commun 23 (2002) 521
68. Hequet Q., Le Q.H., Moullet I., et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 22 (2004) 1864-1871
69. Glanzmann C., Huguenin P., Lutolf U.M., et al. Cardiac lesions after mediastinal irradiation for Hodgkin's disease. Radiother Oncol 30 (1994) 43
70. Heidenreich P.A., Hancock S.L., Lee B.K., et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 42 (2003) 743
71. Byrd III B.F., and Mendes L.A. Cardiac complications of mediastinal radiotherapy. The other side of the coin. J Am Coll Cardiol 42 (2003) 750
72. Gustavsson A., Eskilsson J., Landberg T., et al. Late cardiac effects after mantle radiotherapy in patients with Hodgkin's disease. Ann Oncol 1 (1990) 355
73. Carlson R.G., Mayfield W.R., Normann S., et al. Radiation-associated valvular disease. Chest 99 (1991) 538
74. Sleijfer S. Bleomycin-induced pneumonitis. Chest 120 (2001) 617-624
75. O'Sullivan J.M., Huddar R.A., Norman A.R., et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumors. Ann Oncol 14 (2003) 91-96
76. McDonald S., Rubin P., Phillips T.L., et al. Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys 31 (1995) 1187-1203
77. Roach III M., Gandara D.R., Yuo H.S., et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol 13 (1995) 2606-2612
78. Hirsch A., Vander Els N., Straus D.J., et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol 14 (1996) 1297-1305